Injectable cabotegravir makes progress towards human efficacy studies: doubts about injectable rilpivirine

Researchers
have determined the dose of an injectable formulation of the integrase inhibitor cabotegravir
(formerly GSK744) that will be taken into efficacy trials to see if it can be
used for pre-exposure prophylaxis (PrEP). Studies
in animals were presented earlier this year suggesting that drug levels
stayed high enough in the body for it to